Article | September 9, 2022

Key Financial Considerations For Phase II Clinical Injectable Drug Manufacturing

By Doug Dayhoff, CFO, INCOG BioPharma


When entering a partnership with a contract development and manufacturing organization (CDMO), it is important to understand the different types of manufacturing systems used to produce clinical drug product. In the event of early-phase success, a CDMO’s equipment and facility design can either accelerate or handicap your drug’s future potential and value.

An early-stage manufacturing strategy that maximizes future optionality, reduces time between milestones, and minimizes future risks and workload certainly has material financial value.

This article highlights the importance of scalability and flexibility in the choice of an early-stage manufacturing strategy and how that decision impacts financial outcomes for a drug development program.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma